Trail combinations: The new 'trail' for cancer therapy (review)

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1327-1332

  Refaat, Alaa ^a   Abd rabou, Ahmed ^a   Reda, Asmaa ^a  

^a Zewail City of Science and Technology   (Egypt)

Author keywords

Apoptosis; Cancer therapy; Death receptor 5; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CAMPTOTHECIN; CASPASE; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CELECOXIB; CISPLATIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPROTEGERIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; PROTEIN NOXA; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANGIOGENESIS; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL SURVIVAL; DOWN REGULATION; DRUG POTENTIATION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; UPREGULATION;

EID: 84896261164     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1922     Document Type: Review

References (65)

1. Long JS and Ryan KM: New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene 31: 5045-5060, 2012.
2. Mellier G, Huang S, Shenoy K and Pervaiz S: TRAILing death in cancer. Mol Aspects Med 31: 93-112, 2010.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
4. Rieger J, Ohgaki H, Kleihues P and Weller M: Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol 97: 1-4, 1999.
5. Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, et al: MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One 8: e56817, 2013.
6. Szliszka E, Czuba ZP, Kawczyk-Krupka A, Sieron-Stoltny K, Sieron A and Krol W: Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells. Med Sci Monit 18: BR47-BR53, 2012.
7. He Y, Wang JS, Zhang P, Zhang WJ, Huang QL and Hua ZC: Synergistic apoptotic effect of the combination of diosgenin and TRAIL on non-small-cell lung cancer cell line A549 evaluated with the Chou-Talalay method. Yao Xue Xue Bao 48: 45-51, 2013 (In Chinese).
8. Cai Y, Liu X, Huang W, Zhang K and Liu X: Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim Biophys Sin (Shanghai) 44: 535-543, 2012.
9. Bernardi S, Secchiero P and Zauli G: State of art and recent developments of anticancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 7: 207-217, 2012.
10. Zauli G, Monasta L, Rimondi E, Vecchi Brumatti L, Davanzo R, Demarini S and Secchiero P: Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants. J Hum Lact 29: 350-353, 2013.
11. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al: Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 5: 171ra17, 2013.
12. Strebel A, Harr T, Bachmann F, Wernli M and Erb P: Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry 43: 126-133, 2001.
13. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN and Sycheva AM: Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 14: 778-787, 2009.
14. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
15. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
16. Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 35: 280-288, 2009.
17. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA and Lin Y: Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7: 1156-1163, 2008.
18. Kaufmann T, Strasser A and Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19: 42-50, 2012.
19. Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, et al: Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter 14: 588-595, 2009.
20. Emam H, Zhao QL, Furusawa Y, Refaat A, Ahmed K, Kadowaki M and Kondo T: Apoptotic cell death by the novel natural compound, cinobufotalin. Chem Biol Interact 199: 154-160, 2012.
21. Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer. Oncol Lett 6: 840-844, 2013.
22. Refaat A, Shahat A, Ehsan N, Yassin N, Hammouda F, Abou Tabl E and Ismail S: Phytochemical and biological activities of Crataegus sinaica growing in Egypt. Asian Pac J Trop Med 3: 257-261, 2010.
23. Moon DO, Asami Y, Long H, Jang JH, Bae EY and Kim BY: Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner. Toxicol In Vitro 27: 257-263, 2013.
24. Yamaguchi H and Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279: 45495-45502, 2004.
25. Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S: 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27: 717-728, 2006.
26. Moon DO, Kang CH, Kang SH, Choi YH, Hyun JW and Chang WY, et al: Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx. Toxicol Appl Pharmacol 259: 87-95, 2012.
27. Moon DO, Kim MO, Choi YH and Kim GY: Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther 9: 1583-1595, 2010.
28. Woo JS, Kim SM, Jeong CH, Ryu CH and Jeun SS: Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP-and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. Biochem Biophys Res Commun 431: 354-359, 2013.
29. Sung B, Ravindran J, Prasad S, Pandey MK and Aggarwal BB: Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285: 35418-35427, 2010.
30. Ghosh AP, Klocke BJ, Ballestas ME and Roth KA: CHOP potentially co-operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress. PLoS One 7: e39586, 2012.
31. Martín-Pérez R, Niwa M and López-Rivas A: ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis 17: 349-363, 2012.
32. Sung B, Prasad S, Ravindran J, Yadav VR and Aggarwal BB: Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med 53: 1977-1987, 2012.
33. Kannappan R, Ravindran J, Prasad S, et al: Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther 9: 2196-2207, 2010.
34. Wu GS, Kim K and el-Deiry WS: KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 465: 143-151, 2000.
35. Sung B, Park B, Yadav VR and Aggarwal BB: Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 285: 11498-11507, 2010.
36. Park EJ, Choi KS, Yoo YH and Kwon TK: Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs 24: 260-269, 2013.
37. Safa AR, Day TW and Wu CH: Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8: 37-46, 2008.
38. Wang P, Zhang J, Bellail A, Jiang W, Hugh J, Kneteman NM and Hao C: Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 19: 2237-2246, 2007.
39. Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965, 2008.
40. Yerbes R, López-Rivas A, Reginato MJ and Palacios C: Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells. Cell Death Differ 19: 1908-1916, 2012.
41. Kim J, Kang D, Sun BK, Kim JH and Song JJ: TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex. Cell Signal 25: 372-379, 2013.
42. Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Elliott S, et al: Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res 2: 446-458, 2012.
43. Jane EP, Premkumar DR and Pollack IF: Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-κB signaling pathway. Mol Cancer Ther 10: 198-208, 2011.
44. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
45. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM and Kurzrock R: Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 31: e137-e140, 2013.
46. Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, et al: p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway. Angiogenesis 16: 561-573, 2013.
47. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928, 2006.
48. Ciraolo E, Morello F and Hirsch E: Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 18: 2674-2685, 2011.
49. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A and Loeffler JS: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933, 2004.
50. Alladina SJ, Song JH, Davidge ST, Hao C and Easton AS: TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 42: 337-347, 2005.
51. Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330, 2008.
52. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
53. Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA and Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259, 1994.
54. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
55. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34 (Suppl 5): 9-19, 1997.
56. Cristofanon S and Fulda S: ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 3: e432, 2012.
57. Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, et al: Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 57: 625-636, 2013.
58. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97: 7124-7129, 2000.
59. Hussein MR, Haemel AK and Wood GS: Apoptosis and melanoma: molecular mechanisms. J Pathol 199: 275-288, 2003.
60. Liu X, Yue P, Khuri FR and Sun SY: p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64: 5078-5083, 2004.
61. Takimoto R and El-Deiry WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743, 2000.
62. Guan B, Yue P, Clayman GL and Sun SY: Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 188: 98-105, 2001.
63. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288, 2002.
64. Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ and Cheng AL: Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol 83: 769-777, 2012.
65. Chen KF, Tai WT, Liu TH, Huang HP, Li YC, Shiau CW, et al: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199, 2010.